Recombinant HRP Anti-muscle Actin antibody [EPR8484] - Loading Control (ab185058)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR8484] to muscle Actin - Loading Control
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
- Conjugation: HRP
Related conjugates and formulations
Overview
-
Product name
HRP Anti-muscle Actin antibody [EPR8484] - Loading Control
See all muscle Actin primary antibodies -
Description
HRP Rabbit monoclonal [EPR8484] to muscle Actin - Loading Control -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide within Human muscle Actin aa 350-450. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: P68032 -
Positive control
- NIH 3T3 cell lysate; Human fetal artery, kidney and heart lisates; Human uterus, stomach and skeletal muscle lysates; Human skeletal muscle tissue; Human smooth muscle in colon tissue; Human heart muscle tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: 30% Glycerol (glycerin, glycerine), PBS, 1% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR8484 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab185058 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/10000. Detects a band of approximately 42 kDa (predicted molecular weight: 42 kDa).
|
Notes |
---|
WB
1/10000. Detects a band of approximately 42 kDa (predicted molecular weight: 42 kDa). |
Target
-
Function
Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. -
Involvement in disease
Defects in ACTA1 are the cause of nemaline myopathy type 3 (NEM3) [MIM:161800]. A form of nemaline myopathy. Nemaline myopathies are muscular disorders characterized by muscle weakness of varying severity and onset, and abnormal thread-or rod-like structures in muscle fibers on histologic examination. The phenotype at histological level is variable. Some patients present areas devoid of oxidative activity containg (cores) within myofibers. Core lesions are unstructured and poorly circumscribed.
Defects in ACTA1 are a cause of myopathy, actin, congenital, with excess of thin myofilaments (MPCETM) [MIM:161800]. A congenital muscular disorder characterized at histological level by areas of sarcoplasm devoid of normal myofibrils and mitochondria, and replaced with dense masses of thin filaments. Central cores, rods, ragged red fibers, and necrosis are absent.
Defects in ACTA1 are a cause of congenital myopathy with fiber-type disproportion (CFTD) [MIM:255310]; also known as congenital fiber-type disproportion myopathy (CFTDM). CFTD is a genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions. -
Sequence similarities
Belongs to the actin family. -
Post-translational
modificationsOxidation of Met-46 by MICALs (MICAL1, MICAL2 or MICAL3) to form methionine sulfoxide promotes actin filament depolymerization. Methionine sulfoxide is produced stereospecifically, but it is not known whether the (S)-S-oxide or the (R)-S-oxide is produced. -
Cellular localization
Cytoplasm > cytoskeleton. - Information by UniProt
-
Database links
- Entrez Gene: 58 Human
- Entrez Gene: 11459 Mouse
- Entrez Gene: 29437 Rat
- Omim: 102610 Human
- SwissProt: P68133 Human
- SwissProt: P68033 Mouse
- SwissProt: P68134 Mouse
- SwissProt: P68136 Rat
see all -
Alternative names
- a actin antibody
- ACTA antibody
- ACTA1 antibody
see all
Images
-
All lanes : HRP Anti-muscle Actin antibody [EPR8484] - Loading Control (ab185058) at 1/10000 dilution
Lane 1 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate at 20 µg
Lane 2 : Human kidney tissue lysate - total protein (ab30203) at 20 µg
Lane 3 : Human Fetal Heart at 5 µg
Lane 4 : Human skeletal muscle tissue lysate - total protein (ab29330) at 10 µg
Lane 5 : Skeletal Muscle (Rat) Tissue Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 42 kDa
Additional bands at: 42 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 5 secondsThis blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% Bovine Serum Albumin before being incubated with ab185058 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (1)
ab185058 has been referenced in 1 publication.
- Zauri M et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 524:114-8 (2015). PubMed: 26200337